Xet 20

All types of depression, including reactive & severe depression & depression accompanied by anxiety. Obsessive compulsive disorder (OCD). Panic disorder w/ or w/o agoraphobia. Social anxiety disorder/social phobia. Generalised anxiety disorder. PTSD.

Adult Depression 20 mg daily. Patient not responding may benefit from dose increase in 10 mg daily increments. Max: 50 mg daily. OCD 40 mg daily. Initially 20 mg daily & can be increased in wkly 10 mg daily increments. Doses up to max 60 mg daily may benefit some patient. Panic disorder 40 mg daily. Initially 10 mg daily w/ dose adjusted in wkly 10 mg daily increments according to response. Doses up to max 60 mg daily may benefit some patient. Social anxiety disorder/social phobia 20 mg daily. Patient not responding may benefit from dose increase in 10 mg increments as required. Max: 50 mg daily according to response. Generalised anxiety disorder 20 mg daily. Patient not responding may benefit from dose increase in 10 mg increments as required. Max: 50 mg daily according to response. PTSD Starting & maintenance dose is 20 mg daily (for majority of patient). Patient not responding may benefit from dose increase in 10 mg increments as required. Max: 50 mg daily according to response. Patient w/ renal impairment (CrCl <30 mL/min) or severe hepatic impairment Dose should be restricted to lower end of dose range. Elderly Begin w/ adult starting dose & may be increased by wkly 10 mg daily increments up to 40 mg daily according to response.

Should be taken with food: Preferably taken in the morning. Tab should be swallowed rather than chewed.

Hypersensitivity. Concomitant use w/ MAOIs.

Closely monitor patient for clinical worsening & suicide risk, especially at the beginning of therapy or when dose is changed, until improvement occurs. Avoid abrupt discontinuation; gradually taper when discontinuing treatment over period of several wk or mth. Associated w/ development of akathisia, serotonin syndrome or NMS-like events (rare). Rare reports of hyponatraemia predominantly in elderly. Reports of bleeding abnormalities of the skin & mucous membranes. Do not use in combination w/ serotonin-precursors (eg, L-tryptophan, oxitriptan). Adequately screen patient to determine risk for bipolar disorder prior to initiation of treatment. Not approved for use in treating bipolar depression. Caution in patients w/ epilepsy; narrow angle glaucoma; severe renal impairment; hepatic impairment; history of abnormal bleeding or w/ predisposing conditions; cardiac conditions. Discontinue therapy if patient develops seizure. Little clinical experience w/ concurrent electroconvulsive therapy. Advise patient to avoid driving a car or operating hazardous machinery until reasonably certain that paroxetine does not affect patient adversely. Should not be used during pregnancy unless potential benefit outweighs possible risk. Should not be used in childn & adolescent (<18 yr).

Asthenia, constipation, decreased appetite, diarrhea, dizziness, dry mouth, insomnia, male sexual dysfunction, nausea, somnolence, sweating, tremor, agitation, blurred vision.

Decreased plasma levels w/ fosamprenavir/ritonavir. Increased plasma levels of procyclidine. Elevated plasma levels of thioridazine. Should not be used in combination w/ pimozide.

Antidepressants

N06AB05 - paroxetine ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression.

Rx